Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2010-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00280-009-1168-5PMID 19921195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The CYP2A6[*]4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer

  2009influential reference
• CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1

  2008cited by this paper
• The CYP2A6*4 Allele Is Determinant of S‐1 Pharmacokinetics in Japanese Patients With Non‐small‐cell Lung Cancer

  2008cited by this paper
• Pharmacokinetic Modelling of [2-13C]Uracil Metabolism in Normal and DPD-Deficient Dogs

  2006cited by this paper
• Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations

  2006cited by this paper
• Cytochrome P450 and anticancer drugs.

  2006cited by this paper
• Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen

  2006cited by this paper
• A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer

  2005cited by this paper
• Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer

  2005cited by this paper
• Novel human CYP2A6 alleles confound gene deletion analysis

  2004cited by this paper
• Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

  2004influential reference
• Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

  2004cited by this paper
• Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2-13C-Uracil Breath Test

  2004cited by this paper
• Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro

  2003cited by this paper
• The contribution of cytochrome P450 to the metabolism of tegafur in human liver.

  2003cited by this paper
• Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).

  2003cited by this paper
• An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.

  2002cited by this paper
• Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

  2002cited by this paper
• Characterization of cytochrome P450 2D6 alleles using the Invader system.

  2002cited by this paper
• Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.

  2001cited by this paper
• Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.

  2001cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• A novel single nucleotide polymorphism altering stability and activity of CYP2a6.

  2001cited by this paper
• Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

  2000cited by this paper
• Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.

  2000cited by this paper
• [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].

  1998cited by this paper
• A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

  1998cited by this paper
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

  1998cited by this paper
• Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry.

  1997cited by this paper
• Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.

  1996cited by this paper
• Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

  1987cited by this paper
• Purification and properties of dihydrothymine dehydrogenase from rat liver.

  1981cited by this paper

• Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

  2023cites this paper
• 2-13C-Uracil 呼気テストによるS-1 感受性予測

  2014cites this paper
• An Update on 13 C-Breath Tests: The Transition to Acceptability into Clinical Practice

  2013cites this paper
• Breath Tests to Phenotype Drug Disposition in Oncology

  2013cites this paper
• Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma.

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6

  2012cites this paper
• Pancreatic cancer: chemotherapy and radiotherapy

  2011cites this paper
• How close are we to finding noninvasive markers for upper GI tract cancer?

  2011cites this paper